Assessing Drug-Smoking Interactions Using PBPK Modeling
The prevalence of cigarette smoking remains high globally despite abundant evidence showing that it isn't…
CertaraJuly 29, 2016
Status of QSP Modeling in the Pharmaceutical Industry
A primary cause of failures in pharmaceutical research and development (R&D) has been attributed to…
CertaraJuly 6, 2016
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances
Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…
CertaraJuly 1, 2016
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data
A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…
CertaraJune 1, 2016
Prediction of Drug-drug Interactions Arising From CYP3A Induction Using a Physiologically-based Dynamic Model
Using physiologically-based pharmacokinetic modeling, we predicted the magnitude of drug-drug interactions (DDIs) for studies with…
CertaraJune 1, 2016
Cardiac Safety Simulator
Predicts drug-induced cardiovascular risks early, enabling informed decisions and reducing costly late-stage failures.
CertaraApril 27, 2016
Recent Advances in Development and Application of Physiologically-based Pharmacokinetic (PBPK) Models: A Transition from Academic Curiosity to Regulatory Acceptance
There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the…
CertaraApril 14, 2016
